# US 2022/0064278 A1 · Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064278 A1
- Document ID: US20220064278A1
- Status: Published application
- Kind: A1
- Application number: 17/423,512
- Filed: 2020-01-14
- Published: 2022-03-03
- Earliest claimed: 2019-01-23
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Diane D. Harrison; Elizabeth C. Hsia; Lee-Lian Kim; Kim Hung Lo
- Web page: https://patentgrep.com/patent/US20220064278A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/06: Antipsoriatics
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising amino acid sequence SEQ ID NO:36 and a light chain (LC) comprising amino acid sequence SEQ ID NO:37 in a treatment for active Psoriatic Arthritis (PsA).

## Claims

### Claim 1

A composition for use in a treatment for patients with active Psoriatic Arthritis, the composition comprising at least one pharmaceutically acceptable carrier or diluent and at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising amino acid sequence SEQ ID NO:36 and a light chain (LC) comprising amino acid sequence SEQ ID NO:37, wherein the treatment comprises administering said composition to the patients via IV infusion, and wherein at week 52 of said treatment the patients treated with the anti-TNF antibody have a significant mean change from baseline in total modified van der Heijde-Sharp (vdH-S) score in the patients selected from the group consisting of: patients identified as having remission-low disease activity in Disease Activity in PsA (DAPSA), patients identified as having moderate disease activity in DAPSA, patients identified as having inactive disease activity in PsA Activity Score (PASDAS), patients identified as having moderate disease activity in PASDAS, patients identified as having Minimal Disease Activity (MDA), patients identified as not having MDA, patients identified as having Very Low Disease Activity (VLDA), patients identified as not having VLDA, patients identified as having remission in Clinical Disease Activity Index (CDAI), and patients identified as having low disease activity in CDAI.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the significant mean change from baseline in total modified vdH-S score is selected from the group consisting of: vdH-S=−0.88±2.3(SD) in the patients identified as having remission-low disease activity in DAPSA, vdH-S=−0.48±1.82(SD) in the patients identified as having moderate disease activity in DAPSA, vdH-S=−1.01±2.384(SD) in the patients identified as having inactive disease activity in PASDAS, vdH-S=−0.20±1.965(SD) in the patients identified as having moderate disease activity in PASDAS, vdH-S=−1.16±2.46(SD) in the patients identified as having MDA, vdH-S=0.03±2.44(SD) in the patients identified as not having MDA, vdH-S=−1.49±2.22(SD) in the patients identified as having VLDA, vdH-S=−0.30±2.52(SD) in the patients identified as not having VLDA, vdH-S=−1.06±2.41(SD) in the patients identified as having remission in CDAI, and vdH-S=−0.81±2.12(SD) in the patients identified as having low disease activity in CDAI.

### Claim 3 (depends on 2)

The composition of claim 2, wherein said composition is administered such that said antibody is administered at a dose of 2 mg/kg, at Weeks 0 and 4, then every 8 weeks (q8w) thereafter.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said composition is administered over a period of 30±10 minutes.

### Claim 5 (depends on 3)

The composition of claim 3, wherein said patient is an adult patient that is 18 years of age or older.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the treatment further comprises administering said composition with or without methotrexate (MTX).

### Claim 7 (depends on 1)

The composition of claim 1, wherein the treatment further comprises administering, prior, concurrently or after said (a) administering, at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

### Claim 8

A method for treating a TNF related condition in patients, wherein the TNF related condition is active Psoriatic Arthritis, the method comprising:
(a) determining a total modified van der Heijde-Sharp (vdH-S) score for the patients prior to treating the patients;
(b) treating the patients by administering via intravenous (IV) infusion a composition comprising an anti-TNF antibody having a heavy chain (HC) comprising amino acid sequence SEQ ID NO:36 and a light chain (LC) comprising amino acid sequence SEQ ID NO:37; and,
(c) determining the total modified vdH-S score for the patients at week 52 of said treatment; wherein said patients treated with the composition comprising the anti-TNF antibody achieve a significant mean change from baseline in total modified vdH-S score in the patients selected from the group consisting of: patients identified as having remission-low disease activity in Disease Activity in PsA (DAPSA), patients identified as having moderate disease activity in DAPSA, patients identified as having inactive disease activity in PsA Activity Score (PASDAS), patients identified as having moderate disease activity in PASDAS, patients identified as having Minimal Disease Activity (MDA), patients identified as not having MDA, patients identified as having Very Low Disease Activity (VLDA), patients identified as not having VLDA, patients identified as having remission in Clinical Disease Activity Index (CDAI), and patients identified as having low disease activity in CDAI.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the significant mean change from baseline in total modified vdH-S score is selected from the group consisting of: vdH-S=−0.88±2.3(SD) in the patients identified as having remission-low disease activity in DAPSA, vdH-S=−0.48±1.82(SD) in the patients identified as having moderate disease activity in DAPSA, vdH-S=−1.01±2.384(SD) in the patients identified as having inactive disease activity in PASDAS, vdH-S=−0.20±1.965(SD) in the patients identified as having moderate disease activity in PASDAS, vdH-S=−1.16±2.46(SD) in the patients identified as having MDA, vdH-S=0.03±2.44(SD) in the patients identified as not having MDA, vdH-S=−1.49±2.22(SD) in the patients identified as having VLDA, vdH-S=−0.30±2.52(SD) in the patients identified as not having VLDA, vdH-S=−1.06±2.41(SD) in the patients identified as having remission in CDAI, and vdH-S=−0.81±2.12(SD) in the patients identified as having low disease activity in CDAI.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said composition is administered such that said anti-TNF antibody is administered at dose of 2 mg/kg, at Weeks 0 and 4, then every 8 weeks (q8w) thereafter.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said composition is administered over a period of 30±10 minutes.

### Claim 12 (depends on 10)

The method according to claim 10, wherein said patient is an adult patient that is 18 years of age or older.

### Claim 13 (depends on 10)

The method according to claim 10, further comprising administering said composition with or without methotrexate (MTX).

### Claim 14 (depends on 8)

A method according to claim 8, the method further comprising administering, prior, concurrently or after said (a) administering, at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

### Claim 15

An isolated mammalian anti-TNF antibody for use in a treatment for patients with active Psoriatic Arthritis, the isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising amino acid sequence SEQ ID NO:36 and a light chain (LC) comprising amino acid sequence SEQ ID NO:37, wherein said treatment comprises administering the isolated mammalian anti-TNF antibody to the patients via IV infusion, wherein at week 52 of said treatment the patients treated with the anti-TNF antibody have a significant mean change from baseline in total modified van der Heijde-Sharp (vdH-S) score in the patients selected from the group consisting of: patients identified as having remission-low disease activity in Disease Activity in PsA (DAPSA), patients identified as having moderate disease activity in DAPSA, patients identified as having inactive disease activity in PsA Activity Score (PASDAS), patients identified as having moderate disease activity in PASDAS, patients identified as having Minimal Disease Activity (MDA), patients identified as not having MDA, patients identified as having Very Low Disease Activity (VLDA), patients identified as not having VLDA, patients identified as having remission in Clinical Disease Activity Index (CDAI), and patients identified as having low disease activity in CDAI.

### Claim 16 (depends on 15)

The isolated mammalian anti-TNF antibody of claim 15, wherein the significant mean change from baseline in total modified vdH-S score is selected from the group consisting of: vdH-S=−0.88±2.3(SD) in the patients identified as having remission-low disease activity in DAPSA, vdH-S=−0.48±1.82(SD) in the patients identified as having moderate disease activity in DAPSA, vdH-S=−1.01±2.384(SD) in the patients identified as having inactive disease activity in PASDAS, vdH-S=−0.20±1.965(SD) in the patients identified as having moderate disease activity in PASDAS, vdH-S=−1.16±2.46(SD) in the patients identified as having MDA, vdH-S=0.03±2.44(SD) in the patients identified as not having MDA, vdH-S=−1.49±2.22(SD) in the patients identified as having VLDA, vdH-S=−0.30±2.52(SD) in the patients identified as not having VLDA, vdH-S=−1.06±2.41(SD) in the patients identified as having remission in CDAI, and vdH-S=−0.81±2.12(SD) in the patients identified as having low disease activity in CDAI.

### Claim 17 (depends on 16)

The isolated mammalian anti-TNF antibody of claim 16, wherein the isolated mammalian anti-TNF antibody is administered at a dose of 2 mg/kg, at Weeks 0 and 4, then every 8 weeks (q8w) thereafter.

### Claim 18 (depends on 17)

The isolated mammalian anti-TNF antibody of claim 17, wherein said isolated mammalian anti-TNF antibody is administered over a period of 30±10 minutes.

### Claim 19

The isolated mammalian anti-TNF antibody of 17, wherein said patient is an adult patient that is 18 years of age or older.

### Claim 20

The isolated mammalian anti-TNF antibody of 17, wherein the treatment further comprises administering said isolated mammalian anti-TNF antibody with or without methotrexate (MTX).
